Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT06488638 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2024-07-05
Summary
Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients. In previous research the investigators identified that an interval-based exercise programme led to significant improvements in exercise capacity (Wallis et al Antioxidants. 2023).
An unexpected finding was that in patients with IPF, exercise led to a reduction in blood nitrite concentrations an observation the investigators did not see in non-affected individuals. Research has identified that nitrite concentrations are expected to increase after exercise and the size of this increase is related to an individual's exercise capacity. There is also evidence from healthy individuals and patients with chronic obstructive pulmonary disease (COPD) that nitrate supplementation (a source of nitrite) improves response to exercise training. However, in both these groups an exercise-induced fall in blood nitrite concentrations has not been observed. Hence our finding of an exercise-induced fall in blood nitrite levels in IPF patients suggest that they may be especially sensitive to supplementation with nitrate, commercially available as nitrate-rich beetroot juice (NRBJ).
This current study investigates this in a pilot placebo-controlled, double-blind, randomised, cross-over study of NRBJ on exercise capacity in IPF patients.
Aims In patients with IPF
* Quantify the effect of nitrate supplementation on exercise capacity
* Determine the effect of nitrate supplementation on blood markers of nitric oxide production/metabolism.
* Determine the effect of nitrate supplementation on forearm blood flow. Sample size: n=8 IPF patients, aged 18-85years and medical research breathlessness scale 1-3 Intervention: 3-days (two-times daily) NRBJ or nitrate-depleted placebo juice (both commercially available) with subsequent constant-load exercise test (Primary outcome). Following at least 1 week wash-out period participants will cross-over and repeat.
A cohort (n=8) of age, sex-matched controls without IPF will be enrolled for comparison of forearm blood flow and pre-exercise venous blood samples for biomarkers comparison only.
Number of sites: 1
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
commercially available beetroot juice dietary nitrate supplement
Sponsors & Collaborators
-
NIHR Southampton Respiratory Biomedical Research Centre
collaborator UNKNOWN -
Asthma, Allergy and Inflammation Research (AAIR) Charity
collaborator UNKNOWN -
University Hospital Southampton NHS Foundation Trust
lead OTHER
Principal Investigators
-
Tim JM Wallis, MD, PhD · University Hospital Southampoton
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 28 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-09-30
- Primary Completion
- 2025-09-30
- Completion
- 2026-09-30
More Related Trials
-
Hypoxic Pulmonary Vasoconstriction Pilot Study
NCT03733470 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
NCT03267108 ·Status: TERMINATED ·Phase: PHASE3
-
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
NCT03135860 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude
NCT00724321 ·Status: WITHDRAWN ·Phase: PHASE1
-
Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
NCT00439543 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Iron Status and Hypoxic Pulmonary Vascular Responses
NCT01847352 ·Status: COMPLETED ·Phase: NA
-
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
NCT06643143 ·Status: WITHDRAWN ·Phase: PHASE2
-
Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)
NCT04968210 ·Status: COMPLETED
-
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
NCT04377620 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions
NCT03051711 ·Status: TERMINATED ·Phase: PHASE1
-
Study of GSK2586881 on Acute Hypoxia and Exercise
NCT03000686 ·Status: TERMINATED ·Phase: PHASE1
-
(-)-Epicatechin and Pulmonary Arterial Hypertension
NCT01880866 ·Status: WITHDRAWN ·Phase: PHASE1
-
Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
NCT00071461 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
NCT04358588 ·Status: NO_LONGER_AVAILABLE
-
A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
NCT02676947 ·Status: COMPLETED ·Phase: PHASE2
-
Iloprost Effects on Gas Exchange and Pulmonary Mechanics
NCT01274481 ·Status: COMPLETED ·Phase: PHASE1
-
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
NCT05567367 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation
NCT00582010 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Iron Deficiency In Pulmonary Hypertension
NCT01288651 ·Status: UNKNOWN ·Phase: PHASE4
-
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
NCT01728220 ·Status: COMPLETED ·Phase: PHASE2
-
Iloprost Power 15 in Pulmonary Arterial Hypertension
NCT00709956 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
NCT00748423 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
NCT02267655 ·Status: COMPLETED ·Phase: PHASE1
-
Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension
NCT04715113 ·Status: COMPLETED ·Phase: NA
-
Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
NCT01319045 ·Status: TERMINATED ·Phase: NA